Kimia Farma (KAEF) Launches Stemxera, Strengthening Biotechnology Business

PT Kimia Farma (Persero) Tbk (KAEF) is strengthening its product and service portfolio in the biotechnology sector. This is being achieved through participation in the International Conference Rejaselindo 2026, held from 2–4 April 2026 at the Bali Nusa Dua Convention Centre. The event serves as a scientific forum bringing together medical professionals, researchers, and healthcare practitioners to discuss the latest developments in regenerative medicine.

The launch forms part of Kimia Farma’s commitment to delivering competitive biotechnology-based therapy innovations, while also expanding access to healthcare services for the public. Furthermore, it aims to raise awareness and open up strategic collaboration opportunities with healthcare institutions and academics at both national and global levels.

As part of an integrated healthcare ecosystem, Kimia Farma continues to promote the development of stem cell-based research and clinical trials. Stemxera was developed at the stem cell laboratory facility of RSUPN Dr Cipto Mangunkusumo (RSCM). This facility has obtained a Good Manufacturing Practice (GMP) certificate from the National Agency of Drug and Food Control (BPOM).

In its development, the company emphasises high standards of quality, safety, and efficacy in line with applicable regulations. The product is presented as an innovative regenerative therapy solution, particularly for managing degenerative conditions and advanced medical therapy needs.

“Through Stemxera, we aim to deliver regenerative therapy innovations that are not only scientifically superior but also more widely accessible to the Indonesian public. With an adaptive service approach, we are optimistic that Stemxera can accelerate the utilisation of stem cell therapy across various healthcare facilities,” said Hanadi in a press release on Wednesday (8/4/2026).

Through the launch of Stemxera, the company hopes to further strengthen the independence of the national pharmaceutical industry and contribute to supporting Indonesia’s health resilience. These efforts are pursued through the development and expansion of access to biotechnology-based therapies and innovative, sustainable regenerative treatments.